All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Panobinostat is a HDAC inhibitor used to treat multiple myeloma (MM) and effects expression of several critical genes. The question of its mechanism of action on myeloma cells was addressed in a letter to the editor of Blood, published in May 2017. Estefania Garcia-Guerrero and colleagues from Medizinische Klinik and Poliklinik II, University of Würzburg, Germany, and Institute of Biomedicine Seville, IBIS Hospital, University of Seville, Spain, showed that panobinostat specifically up-regulates CD38 on MM cells and that this increase augments the effect of the monoclonal antibody daratumumab.
Up-regulation of CD38:
Synergy with daratumumab:
In conclusion, the ability of panobinostat to selectively up-regulate CD38 on myeloma cells provided a synergistic effect when administered with daratumumab, and warrants further investigation of this dual treatment regimen.
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?